Invention Grant
- Patent Title: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
-
Application No.: US17036110Application Date: 2020-09-29
-
Publication No.: US11639927B2Publication Date: 2023-05-02
- Inventor: Theresa Rosario-Jansen , David Erick Wright
- Applicant: Horizon Therapeutics USA, Inc.
- Applicant Address: US IL Deerfield
- Assignee: Horizon Therapeutics USA, Inc.
- Current Assignee: Horizon Therapeutics USA, Inc.
- Current Assignee Address: US IL Deerfield
- Agency: Cooley LLP
- Main IPC: C12Q1/62
- IPC: C12Q1/62 ; G01N33/53 ; G01N33/68 ; C12N9/02 ; A61K47/60 ; A61P19/02 ; A61K9/00 ; A61K38/44
Abstract:
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
Public/Granted literature
Information query
